One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology.
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology.
复制标题
Control-IQ高级混合闭环技术的一年实际使用。
DOI：
10.1089/dia.2021.0097
复制
发表时间：
2021-09
影响因子：
5.4
通讯作者：
Kovatchev BP
中科院分区：
文献类型：
--
作者：
Breton MD;Kovatchev BP
背景：Tandem糖尿病护理公司的T：SILM X2™胰岛素泵采用Control-IQ®技术，是一种先进的混合闭环系统，于2020年1月在美国首次商业化。与实际使用该系统相关的纵向血糖结果尚未报道。方法：回顾分析截至2021年2月11日，Control-IQ技术用户将数据上传到Tandem的t：Connect®网络应用程序的情况。用户年龄为6岁，在控制智商技术启动前2周和控制智商技术启动后12个月的连续血糖监测(≥)数据包括在分析中。结果：在9451名符合纳入标准的使用者中，83%患有1型糖尿病，其余的患有2型或其他形式的糖尿病。平均年龄42.6 ± 2 0.8岁，女性占5 2%。在整个12个月的观察期间，自动化时间的中位数为94.2%[四分位数范围，IQR：90.1%-96.4%]，随着时间的推移没有显著变化。在这些用户中，9010人(96.8%)有75%的CGM数据可用，也就是说，有足够的数据来可靠地计算基于CGM的血糖结果。在基线时，控制智商技术使用12个月的中位百分比时间(70-180 mg/dL)是63.6%(智商：49.9%-75.6%)，增加到73.6%(智商：64.4%-81.8%)，随着时间的推移没有显著变化。时间和70 mg/dL的中位数百分比保持一致，∼为1%(IQR0.5%-1.9%)。结论：在这一现实世界的使用分析中，Control-IQ技术保留并在一定程度上超过了随机对照试验中获得的结果，显示出不同类型糖尿病患者的广泛年龄范围内的血糖改善。
Background: The t:slim X2™ insulin pump with Control-IQ® technology from Tandem Diabetes Care is an advanced hybrid closed-loop system that was first commercialized in the United States in January 2020. Longitudinal glycemic outcomes associated with real-world use of this system have yet to be reported. Methods: A retrospective analysis of Control-IQ technology users who uploaded data to Tandem's t:connect® web application as of February 11, 2021 was performed. Users age ≥6 years, with >2 weeks of continuous glucose monitoring (CGM) data pre- and >12 months post-Control-IQ technology initiation were included in the analysis. Results: In total 9451 users met the inclusion criteria, 83% had type 1 diabetes, and the rest had type 2 or other forms of diabetes. The mean age was 42.6 ± 20.8 years, and 52% were female. Median percent time in automation was 94.2% [interquartile range, IQR: 90.1%–96.4%] for the entire 12-month duration of observation, with no significant changes over time. Of these users, 9010 (96.8%) had ≥75% of their CGM data available, that is, sufficient data for reliable computation of CGM-based glycemic outcomes. At baseline, median percent time in range (70–180 mg/dL) was 63.6 (IQR: 49.9%–75.6%) and increased to 73.6% (IQR: 64.4%–81.8%) for the 12 months of Control-IQ technology use with no significant changes over time. Median percent time <70 mg/dL remained consistent at ∼1% (IQR: 0.5%–1.9%). Conclusion: In this real-world use analysis, Control-IQ technology retained, and to some extent exceeded, the results obtained in randomized controlled trials, showing glycemic improvements in a broad age range of people with different types of diabetes.
登录
查看更多内容
影响因子：
16.2
作者：
Danne T;Nimri R;Battelino T;Bergenstal RM;Close KL;DeVries JH;Garg S;Heinemann L;Hirsch I;Amiel SA;Beck R;Bosi E;Buckingham B;Cobelli C;Dassau E;Doyle FJ 3rd;Heller S;Hovorka R;Jia W;Jones T;Kordonouri O;Kovatchev B;Kowalski A;Laffel L;Maahs D;Murphy HR;Nørgaard K;Parkin CG;Renard E;Saboo B;Scharf M;Tamborlane WV;Weinzimer SA;Phillip M
通讯作者：
Phillip M
影响因子：
5.4
作者：
Hovorka, Roman;Chassin, Ludovic J;Pieber, Thomas R
通讯作者：
Pieber, Thomas R
影响因子：
3.8
作者：
Petrovski G;Al Khalaf F;Campbell J;Umer F;Almajaly D;Hamdan M;Hussain K
通讯作者：
Hussain K
影响因子：
7.7
作者：
Steil, Garry M.;Rebrin, Kerstin;Saad, Mohammed F.
通讯作者：
Saad, Mohammed F.
影响因子：
16.2
作者：
Lal, Rayhan A.;Basina, Marina;Wilson, Darrell M.
通讯作者：
Wilson, Darrell M.